Inhibiting the anaphase promoting complex/cyclosome induces a metaphase arrest and cell death in multiple myeloma cells.
EZH2 in normal hematopoiesis and hematological malignancies.
miRNAs in multiple myeloma - a survival relevant complex regulator of gene expression.
Factors influencing extramedullary relapse after allogeneic transplantation for multiple myeloma.
Expression and role of RIP140/NRIP1 in chronic lymphocytic leukemia.
Drug metabolism and clearance system in tumor cells of patients with multiple myeloma.
In vivo treatment with epigenetic modulating agents induces transcriptional alterations associated with prognosis and immunomodulation in multiple myeloma.
The 7p15.3 (rs4487645) association for multiple myeloma shows strong allele-specific regulation of the MYC-interacting gene CDCA7L in malignant plasma cells.
SNaPshot as a Valuable Option for the Identification of Mutations in Myeloma.
DNA repair in diffuse large B-cell lymphoma: a molecular portrait.
Identification of a 20-gene expression-based risk score as a predictor of clinical outcome in chronic lymphocytic leukemia patients.
A DNA repair pathway score predicts survival in human multiple myeloma: the potential for therapeutic strategy.
Identification and characterization of new Leishmania promastigote surface antigens, LaPSA-38S and LiPSA-50S, as major immunodominant excreted/secreted components of L. amazonensis and L. infantum.
The glycome of normal and malignant plasma cells.
DNA methylation score is predictive of myeloma cell sensitivity to 5-azacitidine.
DNA repair pathways in human multiple myeloma: role in oncogenesis and potential targets for treatment.
Gene expression-based prediction of myeloma cell sensitivity to histone deacetylase inhibitors.
Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma.
Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells.
Kruppel-like factor 4 blocks tumor cell proliferation and promotes drug resistance in multiple myeloma.
Gene expression-based risk score in diffuse large B-cell lymphoma.
STEAP1 is overexpressed in cancers: a promising therapeutic target.
Residual malignant and normal plasma cells shortly after high dose melphalan and stem cell transplantation. Highlight of a putative therapeutic window in Multiple Myeloma?
Development of gene expression-based score to predict sensitivity of multiple myeloma cells to DNA methylation inhibitors.
Development of gene expression-based risk score in cytogenetically normal acute myeloid leukemia patients.
Identification of pluripotent and adult stem cell genes unrelated to cell cycle and associated with poor prognosis in multiple myeloma.
Clinical and prognostic role of annexin A2 in multiple myeloma.
New prognostic markers, determined using gene expression analyses, reveal two distinct subtypes of chronic myelomonocytic leukaemia patients.
Critical role of the NOTCH ligand JAG2 in self-renewal of myeloma cells.
Efficient transduction of healthy and malignant plasma cells by lentiviral vectors pseudotyped with measles virus glycoproteins.
The role of fluorescence in situ hybridization and gene expression profiling in myeloma risk stratification.
Genes with a spike expression are clustered in chromosome (sub)bands and spike (sub)bands have a powerful prognostic value in patients with multiple myeloma.
SULFs in human neoplasia: implication as progression and prognosis factors.
A high-risk signature for patients with multiple myeloma established from the molecular classification of human myeloma cell lines.
Osteoclast-gene expression profiling reveals osteoclast-derived CCR2 chemokines promoting myeloma cell migration.
Proliferation is a central independent prognostic factor and target for personalized and risk-adapted treatment in multiple myeloma.
MYEOV is a prognostic factor in multiple myeloma.
Growth factors in multiple myeloma: a comprehensive analysis of their expression in tumor cells and bone marrow environment using Affymetrix microarrays.
NPM1 is overexpressed in hyperdiploid multiple myeloma due to a gain of chromosome 5 but is not delocalized to the cytoplasm.
Atacicept in relapsed/refractory multiple myeloma or active Waldenstrom's macroglobulinemia: a phase I study.
Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis.
APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop.
Induction of angiogenesis by normal and malignant plasma cells.
APRIL is overexpressed in cancer: link with tumor progression.
Embryonic stem cell markers expression in cancers.
The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor.
Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma.
MMSET is overexpressed in cancers: link with tumor aggressiveness.
CD200: a putative therapeutic target in cancer.
Input of DNA microarrays to identify novel mechanisms in multiple myeloma biology and therapeutic applications.
Targeting NF-kappaB pathway with an IKK2 inhibitor induces inhibition of multiple myeloma cell growth.
TACI expression is associated with a mature bone marrow plasma cell signature and C-MAF overexpression in human myeloma cell lines.
CD200 is a new prognostic factor in multiple myeloma.
Heparan sulphate proteoglycans are essential for the myeloma cell growth activity of EGF-family ligands in multiple myeloma.
Microarray-based understanding of normal and malignant plasma cells.
Lymphocytes of dogs immunised with purified excreted-secreted antigens of Leishmania infantum co-incubated with Leishmania infected macrophages produce IFN gamma resulting in nitric oxide-mediated amastigote apoptosis.
Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells.
The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature.
BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.
Survival and proliferation factors of normal and malignant plasma cells.
SNaPshot as a Valuable Option for the Identification of Mutations in Myeloma
RECQ helicases are deregulated in hematological malignancies in association with a prognostic value